心臓マーカー検査市場：製品タイプ、バイオマーカータイプ、用途、地域別、2024年～2031年

心臓マーカー検査市場の評価、2024年～2031年

心血管疾患の頻度の増加、早期発見と予防の取り組みに関する知識の増加が、心臓マーカー検査ソリューションの需要を促進しています。Verified Market Researchのアナリストによると、心臓マーカー検査市場は、2023年の評価額約44億2,000万米ドルを下回り、予測期間中に86億9,000万米ドルの評価額に達する見込みです。

高齢者人口の増加、ライフスタイルの変化、肥満や糖尿病などの危険因子の増加、心臓マーカー検査などの高度診断技術に対する需要の急増により、市場は2024年から2031年にかけてCAGR 8.8%で成長します。

心臓マーカー検査市場定義/概要

心臓マーカー検査は、心筋の損傷やストレスの結果として血流に放出される特定のタンパク質を分析します。トロポニン、クレアチンキナーゼ-MB（CK-MB）、ミオグロビンは、心臓損傷の指標であり、心臓発作、心筋梗塞、不安定狭心症など、さまざまな心血管障害の診断に役立ちます。心臓マーカー検査は、急性冠症候群の早期発見、診断、リスク層別化に最も一般的に使用され、医療従事者ができるだけ早く適切な治療や介入を開始できるようにします。

さらに、心臓マーカー検査は、既知の心血管系疾患を有する患者をモニタリングし、治療効果を評価し、治療方針を決定するために不可欠です。救急治療室、重症治療室、および外来環境での広範な使用は、患者の転帰を改善し、心イベントによる死亡率を低下させる上で重要であることを示しています。

心臓疾患の有病率は心臓マーカー検査市場の成長をどのように促進するか？

心臓発作、脳卒中、その他の心臓関連疾患などの心血管疾患の世界の増加は、心臓マーカー検査市場の主要な促進要因です。心血管疾患は依然として世界の死因の上位を占めているため、早期かつ正確な診断に対する要望が高まっており、これは心臓マーカー検査によって支援することができます。これらの検査は、心臓疾患の重症度を判定し、治療を勧める上で極めて重要です。

ポイントオブケア検査技術の開発と強化は、心臓マーカー検査市場に大きな影響を与えています。POCTは、患者の治療時点またはその近くで迅速な診断検査を可能にし、タイムリーな意思決定と治療開始を可能にします。心臓マーカーのPOCTは便利で迅速かつ効率的であるため、急性冠症候群（ACS）やその他の心臓疾患を抱える患者に恩恵をもたらし、市場の成長を支えています。

さらに、心臓病とその危険因子に対する意識の高まりにより、心臓マーカーの使用を含む予防医療と早期発見の必要性が高まっています。また、世界のヘルスケア支出の増加、特に貧しい国々では、改善された診断ツールへのアクセスが増加しています。各国政府や医療機関は、診断法を含むヘルスケア・インフラやサービスに投資しており、これが心臓マーカー検査市場を後押ししています。

厳格な承認手続きは心臓マーカー検査ソリューションの採用を抑制するか？

新しい心臓マーカー検査技術の開発と採用には、高度な検査機器への多額の財政投資や医療専門家のトレーニングなど、いくつかの運用上のハードルがあります。また、検査結果の正確性と信頼性を保証することは、特にポイント・オブ・ケア環境や、近代的な診断施設へのアクセスが限られている低資源環境では困難であり、これが市場の成長を制限しています。

新しい心筋指標や検査法の規制認可プロセスは厳しく、地域によって大きく異なります。米国のFDA（米国食品医薬品局）や欧州のEMA（欧州医薬品庁）のような機関から規制当局の認可を得るには、臨床的検証や有効性のエビデンスを得る必要があるが、これには時間とコストがかかるため、市場拡大が制限されます。

また、レガシー技術と比較して、心臓市場検査の使用に伴う技術的な複雑さが、世界中で受け入れられるための大きな障壁となっています。同様に、心臓市場検査ソリューションの絶え間ないメンテナンスの必要性と高コストが、予算の制約に直面しているメーカー間での採用を抑制しています。

目次

第1章 世界の心臓マーカー検査市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の心臓マーカー検査市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 心臓マーカー検査の世界市場：製品別

• 概要
• 検査機器
• 試薬とキット
• 免疫蛍光法
• ELISA
• イムノクロマトグラフィー

第6章 心臓マーカー検査の世界市場：タイプ別

• 概要
• トロポニンiおよびT
• CK-MB
• ミオグロビン
• その他のバイオマーカー

第7章 心臓マーカー検査の世界市場：検査タイプ別

• 概要
• ラボ検査
• ポイントオブケア検査

第8章 心臓マーカー検査の世界市場：疾患別

• 概要
• 心筋梗塞
• うっ血性心不全

第9章 心臓マーカー検査の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の心臓マーカー検査市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第11章 企業プロファイル

• Roche Diagnostics Limited
• Abbott Laboratories
• Siemens AG
• Danaher Corporation
• BiomA（C）rieux SA
• Alere Inc.
• LSI Medience Corporation
• Ortho Clinical Diagnostics
• Randox Laboratories Ltd
• Guangzhou Wondfo Biotech Co., Ltd.

第12章 付録

• 関連調査

Cardiac Marker Testing Market Valuation - 2024-2031

The increasing frequency of cardiovascular diseases, along with growing knowledge of early detection and prevention efforts, is driving demand for cardiac marker testing solutions. According to the analyst from Verified Market Research, the cardiac marker testing market is estimated to reach a valuation ofUSD 8.69 Billion over the forecast subjugating around USD 4.42 Billion valued in 2023.

Growing elderly population, lifestyle changes is increasing risk factors including obesity and diabetes, surging demand for advanced diagnostic technology, such as cardiac marker testing, enabling the market to grow at a CAGR of 8.8% from 2024 to 2031.

Cardiac Marker Testing Market: Definition/ Overview

Cardiac marker testing analyses specific proteins released into the bloodstream as a result of heart muscle damage or stress. Troponin, creatine kinase-MB (CK-MB), and myoglobin are indications of cardiac injury that aid in the diagnosis of a variety of cardiovascular disorders, including heart attacks, myocardial infarctions, and unstable angina. Cardiac marker testing is most commonly used for the early detection, diagnosis, and risk stratification of acute coronary syndromes, allowing healthcare providers to commence relevant therapies and interventions as soon as possible.

Furthermore, cardiac marker testing serves as essential for monitoring patients with known cardiovascular illnesses, evaluating treatment efficacy, and directing therapeutic decisions. Its broad use in emergency rooms, critical care units, and ambulatory settings demonstrates its importance in improving patient outcomes and lowering mortality rates from cardiac events.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Prevalence of Cardiac Illnesses Bolster Growth of Cardiac Marker Testing Market?

The global rise in cardiovascular disorders, such as heart attacks, strokes, and other heart-related conditions, is a major driver of the cardiac marker testing market. As cardiovascular disease remains one of the top causes of death worldwide, there is an increased desire for early and precise diagnosis, which can be aided by cardiac marker testing. These tests are crucial in determining the severity of heart problems and making treatment recommendations.

The development and enhancements to point-of-care testing technology have significantly impacted the cardiac marker testing market. POCT enables quick diagnostic testing at or near the point of patient care, allowing for timely decision-making and treatment commencement. POCT for cardiac markers is convenient, fast, and efficient, which benefits patients with acute coronary syndromes (ACS) and other heart problems, supporting market growth.

Furthermore, increased awareness of heart disease and its risk factors is resulting in a greater need for preventative care and early detection, including the use of cardiac markers. Also, increased worldwide healthcare expenditure, particularly in poorer nations, is increasing access to improved diagnostic tools. Governments and healthcare organizations are investing in healthcare infrastructure and services, including diagnostics, which is helping to drive the cardiac marker testing market.

Will Strigent Approval Procedures Restrain Adoption of the Cardiac Marker Testing Solutions?

The development and adoption of new cardiac marker testing technologies encounter several operational hurdles, including a significant financial investment in sophisticated testing equipment and healthcare professional training. Also, assuring the accuracy and reliability of test results is difficult, especially in point-of-care settings or low-resource environments with limited access to modern diagnostic facilities, which restricts market growth.

The regulatory approval process for new cardiac indicators and testing methods is stringent and varies greatly between regions. Obtaining regulatory authorization from agencies such as the FDA (US Food and Drug Administration) in the United States or the EMA (European Medicines Agency) in Europe demands significant clinical validation and evidence of efficacy, which is time-consuming and expensive, limiting market expansion.

Also, the technical complexity associated with the use of cardiac market testing compared to the legacy technologies is creating a major barrier for its acceptance worldwide. Similarly, the need for constant maintenance and high cost of the cardiac market testing solutions is restraining the adoption among manufacturers facing budget constraints.

Category-Wise Acumens

What Factors Contribute to the Dominance of Reagents & Kits Segment in the Market?

According to VMR analysis, the reagents & kits segment is estimated to hold the largest market share in the product segment during the forecast period. Reagents and kits are consumables used in a large number of tests for cardiovascular disease diagnosis, monitoring, and management. Unlike instruments, which are less frequent capital investments, reagents and kits must be replenished constantly. Their higher market share is due to their recurring use, which is driven by the ongoing demand for cardiac marker testing in hospitals, diagnostic laboratories, and point-of-care settings.

Ongoing research and development in the field of cardiovascular diseases is resulting in the identification of new biomarkers as well as improvements in test sensitivity and specificity. This advancement needs the continual update and purchase of new or improved reagents and kits capable of detecting these markers, resulting in high demand and market dominance.

Furthermore, reagents and kits are intended for convenience of use and ease in integration into existing laboratory processes without requiring significant additional investment in new equipment or training. Their simplicity of integration makes them an appealing option for many healthcare professionals.

Which Variables Lead to the Broad Acceptance of Point-of-Care Testing?

The point-of-care testing (POCT) segment is estimated to grow at the highest CAGR in the cardiac marker testing market during the forecast period. POCT facilities provide testing closer to the patient, whether at the bedside, in ambulatory care settings, or community clinics, minimizing the need to send samples to centralized laboratories. This greater accessibility is especially useful in emergencies, where early detection is important for managing acute cardiac events like myocardial infarction. The ease of obtaining quick findings without the requirement for complex laboratory infrastructure makes POCT very appealing.

The short turnaround time of results from point-of-care cardiac marker tests allows for urgent clinical decision-making. In the case of cardiovascular disorders, time is of the essence, and the ability to diagnose and commence therapy swiftly can have a substantial impact on patient outcomes. This promptness can lead to better management of patients with acute cardiac problems, shorter hospital stays, and increased overall healthcare efficiency.

Furthermore, technological advances have greatly increased the accuracy, reliability, and range of POCT for cardiac indicators. Modern point-of-care devices can provide laboratory-quality data for important biomarkers like troponin, natriuretic peptides, and others right at the patient's side. These developments have also made POCT devices more user-friendly and cost-effective, accelerating their adoption in a variety of healthcare settings.

Country/Region-wise Acumens

What Factors help Shape Growth of the Market in North America?

According to VMR analyst, North America is estimated to dominate the cardiac marker testing market during the forecast period. North America has one of the highest rates of cardiovascular disease in the world, owing to an ageing population, lifestyle-related risk factors (such as obesity, physical inactivity, and an unhealthy diet), and a high incidence of comorbid conditions (such as diabetes and hypertension). This high prevalence of CVDs causes a significant demand for early and precise diagnosis, monitoring, and management, which is supporting the region's cardiac marker testing market expansion.

Furthermore, North America, particularly the United States, has a well-developed healthcare infrastructure, with a strong emphasis on innovative diagnostic technology and treatments. This infrastructure enables the widespread availability of cardiac marker testing in a variety of healthcare settings, ranging from top-tier hospitals to community clinics. The availability of cutting-edge medical facilities, together with a robust network of laboratories and point-of-care testing facilities, provides wider access to cardiac marker tests, hence driving their uptake and utilization.

How will Cardiac Marker Testing Market Fare in Asia Pacific?

Asia Pacific is experiencing an increase in prevalence of cardiovascular disease as a result of changing lifestyles, urbanization, and ageing populations. Increased tobacco use, poor diets, and physical inactivity all contribute to a rise in the prevalence of heart disease. The growing incidence of CVDs needs early detection and therapy is driving demand for cardiac marker testing in the region.

Furthermore, countries in Asia Pacific are making considerable investments in healthcare infrastructure, such as hospitals, clinics, and diagnostic centers. This expansion is fueled in part by increased economic capacities and a focus on increasing healthcare access and quality. Access to modern diagnostic techniques such as cardiac marker tests grows in tandem with healthcare infrastructure improvements. This rise is especially evident in emerging economies like China and India, where the healthcare industry is rapidly modernizing and expanding.

Competitive Landscape

The competitive landscape of the cardiac market testing market is defined by a dynamic interplay between numerous companies that strive to develop novel solutions that meet the changing needs of patients and healthcare providers. These players are always researching and developing ways to improve the accuracy, efficiency, and accessibility of cardiac testing devices.

Some of the prominent players operating in the cardiac marker testing market include:

Abbott Laboratories

Hoffmann-La Roche Ltd.

Siemens Healthineers AG

Danaher Corporation

Ortho-Clinical Diagnostics

Beckman Coulter Inc.

bioMerieux SA

Koninklijke Philips N.V.

Trinity Biotech plc

Mercadia BioSciences Inc.

LSI Medience Co., Ltd.

Mindray Medical International Limited

Shenzhen Mindray Bio-Medical Electronics Co.

EKF Diagnostics Holdings plc

DiaSorin S.p.A.

Hytest Limited

Stanbio Laboratory LLC

Streck

Thermo Fisher Scientific Inc.

Latest Developments

In February 2024, Abbott announced the ARCHITECT Myxovirus Multiplex Assay, which detects numerous respiratory viruses at the same time, including influenza A and B, respiratory syncytial virus (RSV), and parainfluenza viruses. This assay can aid healthcare practitioners in distinguishing between cardiac difficulties and respiratory infections, which can sometimes present with identical symptoms.

In February 2024, Siemens Healthineers obtained FDA approval for its Atellica(R) CH SOAPS Assay, a novel test that detects creatine kinase-MB (CK-MB), an important cardiac marker. This assay is specifically developed to be used on the Atellica(R) CH immunoassay analyzer, which provides shorter turnaround times and increased workflow efficiency.

In January 2024, Danaher Corporation, which owns Beckman Coulter, announced the acquisition of PHC Holdings Corporation, a major global manufacturer of life science equipment. This acquisition is expected to boost Danaher's position in the cardiac marker testing market by providing them with a more diverse array of diagnostic solutions.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CARDIAC MARKER TESTING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CARDIAC MARKER TESTING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CARDIAC MARKER TESTING MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Instruments
• 5.3 Reagents and Kits
• 5.4 Immunofluorescence
• 5.5 Elisa
• 5.6 Immunochromatography

6 GLOBAL CARDIAC MARKER TESTING MARKET, BY TYPE

• 6.1 Overview
• 6.2 Troponin I and T
• 6.3 CK-MB
• 6.4 Myoglobin
• 6.5 Other Biomarker

7 GLOBAL CARDIAC MARKER TESTING MARKET, BY TYPE OF TESTING

• 7.1 Overview
• 7.2 Laboratory Testing
• 7.3 Point-Of-Care Testing

8 GLOBAL CARDIAC MARKER TESTING MARKET, BY DISEASE

• 8.1 Overview
• 8.2 Myocardial Infarction
• 8.3 Congestive Heart Failure

9 GLOBAL CARDIAC MARKER TESTING MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL CARDIAC MARKER TESTING MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Roche Diagnostics Limited
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Abbott Laboratories
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Siemens AG
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Danaher Corporation
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 BiomA(C)rieux SA
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Alere Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 LSI Medience Corporation
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Ortho Clinical Diagnostics
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Randox Laboratories Ltd
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Guangzhou Wondfo Biotech Co., Ltd.
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research